Contact
 

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting...

The Bill & Melinda Gates foundation issued a highly targeted strategy for HIV, which states that the "foundation’s number-one global health priority is discovering and introducing vaccines for infectious diseases."  Click the link...

A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention—and provides strategic recommendations for moving...

The International AIDS Vaccine Initiative (IAVI) announces the appointment of Margaret McGlynn, former President of Global Vaccines and Anti-infectives at Merck, to its board of directors.

The U.S. Military HIV Research Program (MHRP) and more than 30 U.S. and international collaborators are initiating intensive follow up studies on RV144 in an effort to find the correlates of protection.  Samples from RV144 are being...

The Enterprise and the New York Academy of Sciences hosted a symposium that brought together HIV vaccine researchers to discuss the latest developments in the field. The meeting summary is below.

Seth Berkley, president and CEO of IAVI appeared on TED to explain how smart advances in vaccine design, production and distribution are bringing us closer than ever to eliminating a host of global threats -- from AIDS to malaria to flu...

Claire Keeton of the Sunday Times (South Africa) blogged about lessons from recent HIV vaccine efficacy trials.  Below is her full report, which can be found here:...

The UNAIDS Executive Director, Mr. Michel Sidibé, released a statement commemorating HIV Vaccine Awareness Day, which said "the best hope of ending the AIDS epidemic lies in a safe and highly effective HIV vaccine."  The full statement is...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account